1h Free Analyst Time
The migraine drugs market in latin america is forecasted to grow by USD 90.1 million during 2025-2030, accelerating at a CAGR of 5.5% during the forecast period. The report on the migraine drugs market in latin america provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by escalating disease prevalence and heightened public awareness, modernization and infrastructure development, technological innovation and rise in biological therapies.
The study identifies the proliferation of calcitonin gene-related peptide antagonists and targeted biologics as one of the prime reasons driving the migraine drugs market in latin america growth during the next few years. Also, integration of digital health ecosystems and personalized telemedicine and increased awareness through who initiatives and local programs will lead to sizable demand in the market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The migraine drugs market in latin america is segmented as below:
By Therapy
- Preventive treatment
- Abortive treatment
By End-User
- Hospitals
- Retail
- Online
By Route Of Administration
- Oral
- Injectable
- Nasal
By Region
- Latin America
The report covers the following areas:
- Migraine drugs market in latin america sizing
- Migraine drugs market in latin america forecast
- Migraine drugs market in latin america industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Therapy
9 Market Segmentation by End-user
10 Market Segmentation by Route of Administration
11 Customer Landscape
12 Geographic Landscape
13 Drivers, Challenges, and Opportunity
14 Competitive Landscape
15 Competitive Analysis
16 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global migraine drugs market in latin america: AbbVie Inc., Amgen Inc., Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck A/S, Kowa Co. Ltd., Mallinckrodt Plc, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Ltd., UCB SA.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is proliferation of calcitonin gene-related peptide antagonists and targeted biologics."
According to the report, one of the major drivers for this market is the escalating disease prevalence and heightened public awareness.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Amgen Inc.
- Amneal Pharmaceuticals Inc.
- Bausch Health Companies Inc.
- Bayer AG
- Daiichi Sankyo Co. Ltd.
- Dr Reddys Laboratories Ltd.
- Eli Lilly and Co.
- GlaxoSmithKline PLC
- H. Lundbeck A/S
- Kowa Co. Ltd.
- Mallinckrodt PLC
- Pfizer Inc.
- Sanofi SA
- Teva Pharmaceutical Ltd.
- UCB SA
